Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer
Prostate cancer (PC) is the most pressing oncourological pathology due to a steady increase in morbidity and mortality from this pathology in the Russian Federation. The detection frequency of the common forms of the disease remains high. The combined chemo-hormonal therapy is the main method of tre...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2018-11-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2754 |
| _version_ | 1797841826592325632 |
|---|---|
| author | B. Ya. Alexeev K. M. Nyushko A. D. Kaprin |
| author_facet | B. Ya. Alexeev K. M. Nyushko A. D. Kaprin |
| author_sort | B. Ya. Alexeev |
| collection | DOAJ |
| description | Prostate cancer (PC) is the most pressing oncourological pathology due to a steady increase in morbidity and mortality from this pathology in the Russian Federation. The detection frequency of the common forms of the disease remains high. The combined chemo-hormonal therapy is the main method of treatment of metastatic prostate cancer. The refractoriness of the tumour to the ongoing castration therapy is an inevitable stage of the course of the disease in all patients receiving androgen deprivation therapy. However, castration therapy aimed at reducing endogenous testosterone in this cohort of patients should be continued. Eligard is one of the most studied drugs to conduct the drug castration therapy in patients with prostate cancer, which efficacy has been proven in numerous clinical studies in both continuous and intermittent mode using depot forms of various durations of action. The article presents a review of clinical studies that assessed the efficacy of Eligard therapy in different regimens and with the use of depot forms of various duration, which demonstrated equal effectiveness of such forms. |
| first_indexed | 2024-04-09T16:38:47Z |
| format | Article |
| id | doaj.art-3faf10450ad84ee58295f780380c8fb2 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:38:47Z |
| publishDate | 2018-11-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-3faf10450ad84ee58295f780380c8fb22023-04-23T06:56:48ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902018-11-010199610010.21518/2079-701X-2018-19-96-1002696Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancerB. Ya. Alexeev0K. M. Nyushko1A. D. Kaprin2National Medical Research Radiological Center, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowHertsen Moscow Research Institute of Oncology (Moscow) - a branch of Hertsen National Medical Research Radiology Center of the Ministry of Health of Russia, MoscowNational Medical Research Radiological Center, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowProstate cancer (PC) is the most pressing oncourological pathology due to a steady increase in morbidity and mortality from this pathology in the Russian Federation. The detection frequency of the common forms of the disease remains high. The combined chemo-hormonal therapy is the main method of treatment of metastatic prostate cancer. The refractoriness of the tumour to the ongoing castration therapy is an inevitable stage of the course of the disease in all patients receiving androgen deprivation therapy. However, castration therapy aimed at reducing endogenous testosterone in this cohort of patients should be continued. Eligard is one of the most studied drugs to conduct the drug castration therapy in patients with prostate cancer, which efficacy has been proven in numerous clinical studies in both continuous and intermittent mode using depot forms of various durations of action. The article presents a review of clinical studies that assessed the efficacy of Eligard therapy in different regimens and with the use of depot forms of various duration, which demonstrated equal effectiveness of such forms.https://www.med-sovet.pro/jour/article/view/2754prostate cancermetastasescastration therapyluteinzin-hormone-releasing hormone analogueseligard |
| spellingShingle | B. Ya. Alexeev K. M. Nyushko A. D. Kaprin Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer Медицинский совет prostate cancer metastases castration therapy luteinzin-hormone-releasing hormone analogues eligard |
| title | Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer |
| title_full | Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer |
| title_fullStr | Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer |
| title_full_unstemmed | Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer |
| title_short | Luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer |
| title_sort | luteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancer |
| topic | prostate cancer metastases castration therapy luteinzin-hormone-releasing hormone analogues eligard |
| url | https://www.med-sovet.pro/jour/article/view/2754 |
| work_keys_str_mv | AT byaalexeev luteinizinghormonereleasinghormoneanaloguesinthetreatmentofpatientswithprostatecancer AT kmnyushko luteinizinghormonereleasinghormoneanaloguesinthetreatmentofpatientswithprostatecancer AT adkaprin luteinizinghormonereleasinghormoneanaloguesinthetreatmentofpatientswithprostatecancer |